How much is an FDA short­cut worth to drug de­vel­op­ers hus­tling to an OK? Hold­ing steady at $125M, cash

The mar­ket for pri­or­i­ty re­view vouch­ers is hold­ing steady at $125 mil­lion per deal.

That’s what Bio­Marin just re­ceived for its PRV, sold off to an uniden­ti­fied buy­er look­ing to slash 4 months off of a reg­u­lar drug re­view. And it’s close to twice what the com­pa­ny reaped in 2014 when they sold their first PRV to Re­gen­eron $REGN for $67.5 mil­lion.

Bio­Marin $BM­RN got the PRV hand­ed to it for the re­cent ap­proval of Brineu­ra for late in­fan­tile neu­ronal ceroid lipo­fus­ci­nosis type 2, or CLN2. And they plan to use the $100 mil­lion they’ll clear in prof­it to fund the pipeline work at Bio­Marin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER